MedPath

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

Phase 2
Completed
Conditions
Diabetic Macular Edema
Interventions
Drug: Sham injection
Procedure: Laser Photocoagulation
Registration Number
NCT00464685
Lead Sponsor
Allergan
Brief Summary

This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
253
Inclusion Criteria
  • 18 years of age or older with diabetic macular edema
  • Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse)
  • Visual acuity in other eye no worse than 20/200
Exclusion Criteria
  • Known anticipated need for ocular surgery within next 12 months
  • History of glaucoma or current high eye pressure requiring more than 1 medication
  • Uncontrolled systemic disease
  • Known steroid-responder
  • Use of systemic steroids - Use of Warfarin/Heparin

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham Implant and Laser PhotocoagulationLaser PhotocoagulationInitial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
Sham Implant and Laser PhotocoagulationSham injectionInitial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
700 µg Dexamethasone Implant and Laser PhotocoagulationLaser PhotocoagulationInitial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
700 µg Dexamethasone Implant and Laser PhotocoagulationDexamethasoneInitial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
Primary Outcome Measures
NameTimeMethod
Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study EyeBaseline, Month 12

BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in the Focal Leakage Area in the Study EyeBaseline, Month 12

Focal leakage area in the study eye is assessed using fluorescein angiography. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.

Change From Baseline in Central Subfield Retinal Thickness in the Study EyeBaseline, Month 12

Central subfield retinal thickness is assessed in the study eye by Optical Coherence Tomography (OCT). The central subfield is an area in the retina (back of the eye). OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.

Time to Retreatment in the Study Eye12 Months

Time to retreatment in the study eye is defined as the number of days between the initial treatment and re-treatment with the study medication.

Change From Baseline in BCVA in the Study EyeBaseline, Month 12

BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.

© Copyright 2025. All Rights Reserved by MedPath